证券代码：002099 证券简称：海翔药业 公告编号：2025-027 浙江海翔药业股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、重要提示 1、本次股东大会召开期间，没有增加、否决和变更议案。 2、本次股东大会未出现涉及变更前次股东大会决议的情形。 3、根据《上市公司股份回购规则》的有关规定，上市公司回购的股份自过 户至上市公司回购专用账户之日起即失去其权利，不享有股东大会表决权，在计 算股东大会股权登记日的总股本时应扣减回购专用账户中已回购股份，并以此为 准计算股东大会决议的表决结果。截至 2025 年 5 月 14 日，公司已累计回购公司 股份 31,478,531 股，存放于公司回购专用证券账户中。故截止股权登记日，本 次股东大会有效表决权总股数为 1,587,236,722 股。 二、会议召开情况 1、召开时间：2025 年 5 月 21 日下午 14:30。 2、召开地点：浙江省台州市椒江区海虹大道71号台州市前进化工有限公司 会议室。 3、召开方式：本次股东大会采取现场投票和网络投票相结合的方式 ...

法律意见书 浙江天册律师事务所 关于 浙江海翔药业股份有限公司 2024 年年度股东大会的 法律意见书 浙江天册律师事务所 关于浙江海翔药业股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0815 号 致：浙江海翔药业股份有限公司 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所（以下简称"本所"）接受浙江海翔药业股份有限公司（以 下简称"海翔药业"或"公司"）的委托，指派本所律师姚毅琳、吴婧参加公司 2024 年年度股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规则》 （以下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求出具本 法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员 的资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议 所审议的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 ...

证券代码：002099 证券简称：海翔药业 公告编号：2025-026 浙江海翔药业股份有限公司 关于 2020 年员工持股计划存续期的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次员工持股计划的股票来源为公司回购专用证券账户中已回购的股份。 2020年11月23日，公司收到中国证券登记结算有限责任公司深圳分公司出具的 《证券过户登记确认书》，公司回购专用证券账户中所持有的回购股票已于2020 年11月20日以非交易过户形式过户至公司开立的员工持股计划专户，过户股数为 63,005,888股，占公司总股本的3.89%。具体内容详见巨潮资讯网及2020年11月 24日《证券时报》《中国证券报》《上海证券报》《证券日报》刊登的《关于2020 年员工持股计划非交易过户完成的公告》（公告编号：2020-059）。 截至本公告披露日，本次员工持股计划持有公司股份29,523,688股，约占公 司总股本的1.82%。 （二）本次员工持股计划存续期情况 浙江海翔药业股份有限公司（以下简称"公司"）于2020年7月20日分别召 开了第六届董事会第七次会议和第 ...

Group 1: Company Overview - In 2024, the company achieved a revenue of 1.938 billion CNY, a decrease of 10.75% year-on-year [1] - The net profit attributable to shareholders was -330 million CNY, an increase of 21.38% year-on-year [1] - In Q1 2025, the company reported a revenue of 486 million CNY and a net profit of 9.23 million CNY [1] Group 2: Product Sales and Pipeline - The sales of the Penem series have been under pressure, but a slight recovery is expected starting Q2 2025 [2] - Clindamycin maintains strong sales momentum with high capacity utilization [2] - The company has a diverse pipeline covering anti-infection, diabetes, dermatology, ophthalmology, and psychiatric medications, with products at various R&D stages [2] Group 3: CMO/CDMO Business - The company is one of the earliest in China to engage in CMO/CDMO, having established a partnership with Germany's BI in 2008 [2] - There has been a strong demand growth for existing products from strategic customers, with several new projects in the pipeline [2] Group 4: Formulation Sales and Strategy - The company does not plan to build a large sales team for formulations but will focus on participating in centralized procurement and collaborating with other sales enterprises [2] - The formulation product Voglibose tablets achieved sales of nearly 8 million CNY, marking the first large-scale sales product for the company [2] Group 5: Future Capital Expenditure - The company plans to maintain low capital expenditures in the coming years, focusing on optimizing the supply chain and introducing new products [2] Group 6: Dye Business Performance - In Q1, the sales of the KN-R dye series saw a slight year-on-year increase, with prices recovering [3] - The company will continue to monitor price trends and adjust production plans while enhancing the value chain [3]

Core Viewpoint - The article highlights a trend of decreasing shareholder accounts in several companies, indicating a concentration of shares among fewer investors, with some companies experiencing a significant decline over multiple periods [1][2]. Group 1: Shareholder Account Trends - A total of 101 companies reported their latest shareholder account numbers as of May 10, with 14 companies showing a continuous decline for more than three periods, and some experiencing a drop for up to seven periods [1]. - Notable companies with prolonged declines include Kangxin New Materials, which has 44,113 shareholders, down 26.72% over seven periods, and Dingxin Communications, with 30,474 shareholders, down 21.81% over the same duration [1][2]. - Other companies with significant declines in shareholder accounts include Guotou Intelligent and Changcheng Securities, among others [1]. Group 2: Market Performance - Among the companies with decreasing shareholder accounts, only one has seen its stock price rise, while 13 have experienced declines, with HaiXiang Pharmaceutical showing a notable increase of 1.76% [1]. - In terms of relative performance against the Shanghai Composite Index, only one company outperformed the index, with HaiXiang Pharmaceutical achieving a relative return of 2.93% [1][2]. Group 3: Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery equipment, pharmaceuticals, and communications, with three, two, and two companies respectively [2]. - The distribution of these companies shows that eight are listed on the main board and six on the ChiNext board [2]. Group 4: Detailed Company Data - A table lists companies with their latest shareholder accounts, percentage changes, consecutive decline periods, and stock performance, highlighting significant declines for companies like Naipu Mining (-5.40%), Rundu Co., Ltd. (-4.85%), and Aotexun (-1.90%) [2][3]. - Kangxin New Materials and Dingxin Communications are among those with the longest consecutive declines, with respective declines of 0.34% and 0.40% in the latest period [3].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司截至上月末的回购股份进展情况公告如下： 一、回购公司股份的进展情况 证券代码 ...

Core Insights - Haisheng Pharmaceutical reported a revenue of 1.938 billion yuan for 2024, a year-on-year decline of 10.75% [1] - The company recorded a net loss attributable to shareholders of 330 million yuan, narrowing by 21.38% year-on-year [1] - The basic earnings per share stood at -0.21 yuan [1] Financial Performance - The decline in performance was primarily due to multiple factors impacting the pharmaceutical and dye industries, with intense market competition leading to price pressures [4] - Total assets at the end of 2024 were 7.456 billion yuan, down 0.85% year-on-year, while total liabilities increased by 21.2% to 2.324 billion yuan, resulting in a debt-to-asset ratio of 31.2% [4] - The net cash flow from operating activities was 175 million yuan, a decrease of 27.31% year-on-year, mainly due to increased asset impairment losses and depreciation [4] - Cash flow from financing activities saw a significant decline of 96.51%, while cash flow from investing activities worsened from -128 million yuan to -527 million yuan [4] Business Segments - The pharmaceutical segment generated revenue of 1.368 billion yuan, down 11.77% year-on-year, accounting for 70.59% of total revenue [4] - The dye segment reported revenue of 551 million yuan, a decline of 8.80%, representing 28.47% of total revenue [4] - Key products in the dye segment, such as Reactive Brilliant Blue KN-R, maintained a high market share with double-digit sales growth [4] Research and Development - R&D expenditure for 2024 was 129 million yuan, constituting 6.68% of total revenue [5] - The company is focusing on the development of specialty APIs, generics, and innovative drugs, with new projects like a peptide platform and expansion into ophthalmic, psychiatric, and cardiovascular applications [5]

Group 1 - The company raised a total of RMB 1,026.87 million through a non-public offering of 99.89 million shares at a price of RMB 10.28 per share, with net proceeds amounting to RMB 1,014.40 million after deducting fees [2][3] - The company has established a dedicated account for the management of raised funds, signing tripartite and quadripartite supervision agreements with relevant banks and sponsors to ensure proper fund usage [3][4] - As of December 31, 2024, the company maintained one dedicated account for the raised funds [4] Group 2 - The company reported that the actual use of raised funds has been delayed for several projects, including the "Pharmaceutical Comprehensive R&D Center" and "Environmental Facility Renovation Project," due to strategic adjustments and external factors [5][6] - The "Pharmaceutical Comprehensive R&D Center" project was transferred to a subsidiary, and the implementation location was changed, leading to delays in investment progress [5][6] - The company stated that the benefits of certain projects cannot be individually accounted for, as their effectiveness is reflected indirectly through product quality improvements [7][10] Group 3 - The company reported a net loss of RMB 330.27 million for the year 2024, with total revenue of RMB 1,938.47 million [24][28] - The company proposed not to distribute cash dividends for 2024 due to the reported losses, aligning with its dividend policy [28] - The company has established a robust internal control system, ensuring compliance with relevant laws and regulations [31]

Core Viewpoint - Zhejiang Haixiang Pharmaceutical Co., Ltd. faces significant challenges in 2024, including declining revenue, increased competition, and a need to enhance profitability despite some improvements in financial metrics [1] Financial Performance Summary - Revenue decreased to 1,938,465,657.86 CNY in 2024, down 10.75% from 2,171,886,869.45 CNY in 2023, indicating competitive pressure in both pharmaceutical and dye sectors [2] - Net loss narrowed to -330,267,195.37 CNY, an improvement of 21.38% from -420,055,857.71 CNY in 2023, but the company remains in a loss position [3] - Basic and diluted earnings per share were both -0.21 CNY, showing a 19.23% improvement from -0.26 CNY in 2023, yet still reflect poor shareholder returns [4] Expense Analysis - Sales expenses increased by 13.81% to 33,253,110.97 CNY, indicating a greater investment in market promotion, although this has not yet translated into revenue growth [5] - Management expenses decreased by 5.36% to 307,458,090.96 CNY, suggesting effective internal management and cost control [6] - Financial expenses significantly dropped by 91.79% to -60,065,121.40 CNY, primarily due to increased exchange gains, positively impacting profits [7] Research and Development - R&D expenses rose by 12.01% to 129,445,758.14 CNY, reflecting the company's commitment to innovation across various product lines [8] Cash Flow Analysis - Net cash flow from operating activities decreased by 27.31% to 174,834,870.57 CNY, indicating weakened cash generation capabilities [9] - Net cash flow from investing activities worsened by 311.34% to -527,393,406.00 CNY, necessitating a review of investment strategies [10] - Net cash flow from financing activities fell by 96.51% to 3,461,869.72 CNY, highlighting financial pressure and the need for careful cash management [11]

浙江海翔药业股份有限公司 2024年度独立董事述职报告（钱建民） 作为浙江海翔药业股份有限公司(以下简称"公司")的第七届董事会独立董 事，本人严格按照《公司法》《上市公司独立董事管理办法》等相关法律法规和 《公司章程》《独立董事工作制度》的规定和要求，诚信、勤勉、独立地履行职 责，积极关注公司的经营业务及发展情况，切实维护公司整体利益以及全体股东 特别是中小股东的合法权益，本人现就2024年度独立董事履职情况述职如下： 一、基本情况 报告期内，本人任职情况均符合《上市公司独立董事管理办法》第六条规定 的独立性要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席会议的情况 1、出席董事会及股东大会情况 2024年度，公司共召开5次董事会会议，2次股东大会。本人出席会议情况如 下表： | 本报告期 | | 以通讯方 | | | 是否连续 | | | --- | --- | --- | --- | --- | --- | --- | | | 现场出 | | 委托出 | 缺席次 | 两次未亲 | 出席股东 | | 应参加董 | 席次数 | 式参加次 | 席次数 | 数 | 自参加会 | 大会次数 | | 事 ...